Publications
Complete list of publications
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease
Perier C., Bové J., Wu D.C., Jackson-Lewis V., Dehay B., Choi D.G., Rathke-Hartlieb S, Bouillet P, Strasser A,. Schulz J.B., Przedborski S., and Vila M. Proceedings of the National Academy of Sciences USA (in press)
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage.
Perier C., Tieu K., Guegan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S. and Vila M.
Proceedings of the National Academy of Sciences USA, 102(52):19126-19131 (2005)
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease.
Choi D.-K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.C., Jackson-Lewis V., Vila M., Von Sattel J.P., Heinecke J.W. and Przedborski S.
Journal of Neuroscience, 25(28):6594-600 (2005)
Overexpression of HAHD II/ABAD rescues mitochondrial respiration and dopaminergic neurons in the MPTP model of Parkinson’s disease.
Tieu K., Perier C., Vila M., Zhang H.P., Teismann P., Caspersen C., Jackson-Lewis V., Stern D.M., Yan S.D. and Przedborski S.
Annals of Neurology, 56(1):51-60 (2004)
JNK-mediated induction of COX-2 is required for neurodegeneration in a mouse model of Parkinson’s disease.
Hunot S., Vila M., Teismann P. Davis R.J., Hirsch E.C., Przedborski S., Rakic P., and Flavell R.A.
Proceedings of the National Academy of Sciences USA, 101(2):665-70 (2004)
Genetic clues to the pathogenesis of Parkinson’s Disease.
Vila M. and Przedborski S.
Nature Medicine, 10 Suppl:S58-62 (2004)
Neurodegeneration: what does it mean?
Vila M.
Neurología, 19(3):89-91 (2004)
Interfering with programmed cell death in neurodegenerative diseases: insights from experimental animal models.
Vila M.
Drug Discovery Today, 9(12):513-514 (2004)
MPTP as a Mitochondrial Neurotoxic Model of Parkinson’s Disease.
Przedborski S., Tieu K., Perier C. and Vila M.
Journal of Bioenergetics and Biomembranes, 36(4):375-9 (2004)
D-ß-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson’s disease
Tieu K., Caspersen C., Teismann P, Wu D.C., Perier C., Naini A., Vila M., Jackson-Lewis V., Ramasamy R. and Przedborski S.
Journal of Clinical Investigation, 112(6):892-901 (2003)
Neurotoxic contribution of NADPH oxidase-derived oxidative stress in the MPTP model of Parkinson’s disease.
Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H. and Przedborski S.
Proceedings of the National Academy of Sciences USA, 100(10):6145-50 (2003)
Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration.
Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V. and Przedborski S.
Proceedings of the National Academy of Sciences USA, 100(9):5473-8 (2003)
Free radicals and nitric oxide toxicity in Parkinson’s disease.
Przedborski S., Jackson-Lewis V., Vila M., Wu D.C., Teismann P., Tieu K., Choi D.G. and Cohen O.
Advances in Neurology, 91:83-94 (2003)
Neurodegeneration: what is it and where are we?
Przedborski S., Vila M. and Jackson-Lewis V.
Journal of Clinical Investigation, 111(1):3-10 (2003)
Apoptosis as therapeutic target.
Vila M.
Neurología, 18:186-193 (2003)
Pathogenic role of glial cells in Parkinson’s Disease.
Teismann P., Tieu K., Cohen O., Choi D.K., Wu D.C., Marks D., Vila M., Jackson-Lewis V. and Przedborski S.
Movement Disorders, 18(2):121-9 (2003)
Targeting programmed cell death in neurodegenerative diseases.
Vila M. and Przedborski S.
Nature Reviews in Neuroscience, 4(5):365-75 (2003)
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson’s disease.
Przedborski S. and Vila M.
Annals of the New York Academy of Sciences, 991:189-98 (2003)
COX-2 and Neurodegeneration in Parkinson’s Disease.
Teismann P., Vila M., Choi D.K., Tieu K., Wu D.C., Jackson-Lewis V. and Przedborski S.
Annals of the New York Academy of Sciences, 991:272-7 (2003)
The rotenone model of Parkinson’s disease.
Perier C., Bové J., Vila M. and Przedborski S.
Trends in Neuroscience, 26(7):345-6 (2003)
Resistance of -synuclein null mice to the parkinsonian neurotoxin MPTP.
Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K., Staal R., Tieu K., Schmitz Y., Yuan C.A., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R. and Hen R.
Proceedings of the National Academy of Sciences USA, 99:14524-14529 (2002)
Instrumental activation of Bid by caspase-1 in a transgenic mouse model of ALS.
Guegan C., Vila M., Teismann P., Chen C., Onténiente B., Li M., Friedlander R.M. and Przedborski S.
Molecular and Cellular Neuroscience, 20(4):553-562 (2002)
Increased Expression and Redistribution of the Antiapoptotic Molecule Bcl-x(L) in Parkinson'sDisease.
Hartmann A., Mouatt-Prigent A., Vila M., Abbas N., Perier C., Faucheux B.A., Vyas S. and Hirsch E.C.
Neurobiology of Disease, 10(1):28-32 (2002)
Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA.
Gourfinkel-An I., Vila M., Faucheux B., Duyckaerts C., Viallet F., Hauw J.J., Brice A., Agid Y. and Hirsch E.C.
Journal of Neurochemistry, 80(3):466-76 (2002)
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H. and Przedborski S.
Journal of Neuroscience, 22(5):1763-71 (2002)
Tyrosine hydroxylase.
Jackson-Lewis V., Vila M., and Przedborski S. Wiley
Encyclopedia of Molecular Medicine, p.3283-3293 (2002)
Glial cell response: A pathogenic factor in Parkinson's disease.
Wu D.C., Tieu K., Cohen O., Choi D.K., Vila M., Jackson-Lewis V., Teismann P., Przedborski S.
Journal of Neurovirology, 8(6):551-8 (2002)
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor fluctuations in parkinsonian rats.
Marin C., Jiménez A., Bonastre M., Vila M., Hirsch E.C., Agid Y. and Tolosa E.
Synapse, 42(1):40-47 (2001)
Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis.
Guegan C., Vila M., Rosoklija G., Hays A.P. and Przedborski S.
Journal of Neuroscience, 21(17):6569-6576 (2001)
Lack of nigral pathology in transgenic mice expressing human -synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y.*, Vila M.*, Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., Farrer M., Hardy J., Duff K.,
Przedborski S. and Di Monte D.A. Neurobiology of Disease, 8:535-539 (2001)
Bax ablation prevents dopaminergic neurodegeneration in the MPTP mouse model of Parkinson´s disease.
Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J. and Przedborski S.
Proceedings of the National Academy of Sciences USA, 98(5):2837-2842 (2001)
Oxidative post-translational modifications of -synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease.
Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldetti R., Vukosavic S., Souza J.M., Jackson-Lewis V., Lee V.M.Y. and Ischiropoulos H.
Journal of Neurochemistry, 76:637-640 (2001)
The last decade in Parkinson’s disease research: basic sciences.
Przedborski S. and Vila M.
Advances in Neurology, 86:177-186 (2001)
The role of glial cells in Parkinson’s disease.
Vila M., Jackson-Lewis V., Guegan C., Teismann P., Wu D.C., Choi D.G., Tieu K. and Przedborski S.
Current Opinion in Neurology, 14:483-489 (2001)
Engineered modeling and the secrets of Parkinson’s disease.
Vila M., Wu D.C. and Przedborski S.
Trends in Neuroscience, 24(11): S49-S55 (2001)
MPTP: a review of its mechanisms of neurotoxicity.
Przedborski S. and Vila M.
Clinical Neuroscience Research, 1(6):407-418 (2001)
The indirect basal ganglia pathway in dopamine D(2) receptor-deficient mice.
Murer M.G., Dziewczapolski G., Saline P., Vila M., Tseng K.Y., Ruberg M., Rubinstein M., Kelly M.A., Grandy D.K., Low M.J., Hirsch E.C., Raisman-Vozari R. and Gershanik O.
Neuroscience, 99(4):643-50 (2000)
Developmental cell death in dopaminergic neurons of the substantia nigra of mice.
Jackson-Lewis V., Vila M., Djaldetti R., Guegan C., Liberatore G., Liu J., O’Malley K.L., Burke R.E. and Przedbosrki S.
Journal of Comparative Neurology, 424(3):476-488 (2000)
Metabolic activity of excitatory parafascicular and pedunculopontine inputs to subthalamic nucleus in a rat model of Parkinson’s disease.
Orieux G., François C., Feger J., Yelnik J., Vila M., Ruberg M., Agid Y. and Hirsch E.C.
Neuroscience, 97(1):79-88 (2000)
Functional activity of zona incerta neurons is altered after nigrostriatal denervation in hemiparkinsonian rats.
Perier C., Vila M., Feger J., Agid Y. and Hirsch E.C.
Experimental Neurology, 162(1):215-224 (2000)
Time course changes in metabolic and electrophysiologic neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra.
Vila M., Perier C., Feger J., Yelnik J., Faucheux B., Ruberg M., Raisman-Vozari R., Agid Y. and Hirsch E.C.
European Journal of Neuroscience, 12(1):337-344 (2000)
Alpha-Synuclein upregulation in substantia nigra dopaminergic neurons following the administration of the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Vila M., Vukosavic S., Jackson-Lewis V., Jakowec M. and Przedborski S.
Journal of Neurochemistry, 74:721-729 (2000)
The parkinsonian toxin MPTP: action and mechanism.
Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S and Almer G.
Restorative Neurology and Neuroscience, 16(2):135-142 (2000)
A new look at the pathogenesis of Parkinson’s disease.
Przedborski S., Vila M., Jackson-Lewis V. and Dawson T. M.
Trends in Pharmacological Sciences, 21(5):165 (2000)
Metabolic changes in the basal ganglia following nigrostriatal denervation.
Hirsch E.C., Périer C., Orieux G., François C., Féger J., Yelnik J., Vila M., Levy R., Tolosa E., Marin C., Herrero M.T., Obeso J.A. and Agid Y.
Trends in Neuroscience, 23(10 Suppl):S78-85 (2000)
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson´s disease.
Liberatore G.T., Jackson Lewis, V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.J., Dawson V.L., Dawson T.M and Przedborski S.
Nature Medicine, 5(12):1403-1409 (1999)
Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia.
Vila M., Marin C., Ruberg M., Jimenez A., Raisman-Vozari R., Agid Y.,
Tolosa E and Hirsch E.C. Journal of Neurochemistry, 73:344-352 (1999)
Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and non-human primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA.
Vila M., Levy R., Herrero M.T., Ruberg M., Faucheux B., Obeso J.A., Agid Y. and Hirsch E.C.
Journal of Neuroscience, 17 (2):765-773 (1997)
Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states.
Levy R., Hazrati L.N., Herrero M.T., Vila M., Hassani O.K., Mouroux M., Ruberg M., Asensi H., Agid Y., Féger J., Obeso J.A., Parent A. and Hirsch E.C.
Neuroscience, 76 (2):335-343 (1997)
Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non human primates: a cytochrome oxidase histochemistry study.
Vila M., Levy R., Herrero M.T., Faucheux B., Obeso J.A., Agid Y. and Hirsch E.C.
Neuroscience, 71 (4): 903-912 (1996)
Consequences of nigrostriatal denervation on the GABAergic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes.
Vila M., Herrero M.T., Levy R., Faucheux B., Ruberg M., Guillen J., Luquin M.R., Guridi J., Javoy-Agid F., Agid Y., Obeso J.A. and Hirsch E.C.
Neurology, 46:802-809 (1996)
Localization of monoamine oxidases in human peripheral tissues.
Saura J., Nadal E., van den Berg B., Vila M., Bombi J.A. and Mahy N.
Life Sciences, 59(16):1341-1349 (1996)
Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis.
Guridi J., Herrero M.T., Luquin M.R., Guillen J., Ruberg M., Laguna J., Vila M., Javoy-Agid F., Agid Y., Hirsch E.C. and Obeso J.A.
Brain, 119:1717-1727 (1996)
Differential striatal expression of Methionine-enkephaline and substance P RNA messengers in Parkinson's disease.
Levy R., Vila M., Herrero M.T., Faucheux B., Agid Y. and Hirsch E.C.
Neuroscience Letters, 199:220-224 (1995)
